[{"id":"9f422a88-402d-4776-a63e-899f8ce422df","acronym":"NCI-2014-01147","url":"https://clinicaltrials.gov/study/NCT02159495","created_at":"2021-01-18T10:03:02.202Z","updated_at":"2024-07-02T16:35:21.732Z","phase":"Phase 1","brief_title":"Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","source_id_and_acronym":"NCT02159495 - NCI-2014-01147","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["FLT3 • CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • MB-102 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-01-30"}]